Kodiak Sciences reports Q4 net loss of $59.5M; outlines Phase 3 plans for tarcocimab and KSI-501

Kodiak Sciences Inc.

Q4 2023 net loss $59.5M ($1.13/share) vs $70.4M ($1.35/share) in Q4 2022; R&D expenses fell to $46.6M.
Cash and equivalents $285.5M; company believes sufficient to fund operations into 2026.
Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively enrolling; uses go-to-market formulation.
Phase 3 DAYBREAK study in wet AMD (KSI-501 vs tarcocimab vs aflibercept) targeted to start mid-2024 after FDA discussions.
Phase 1b study of KSI-101 planned for Q2 2024; dual pivotal studies targeted for later 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kodiak Sciences Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2023 and business highlights.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-037608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.